Widespread use of fluoroquinolones versus emerging resistance in pneumococci

Clinical Infectious Diseases

Volumn 35, Issue 12, 2002, Pages 1505-1511

  Goldstein, Ellie J C ^a,b,c   Garabedian Ruffalo, Susan M ^b  

^a Santa Monica UCLA Medical Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG SURVEILLANCE PROGRAM; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; MORTALITY; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; STREPTOCOCCUS PNEUMONIAE;

EID: 0037115152     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344768     Document Type: Review

References (53)

1. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001;33:757-62.
2. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001; 45:1721-9.
3. Chen DK, McGeer AL, De Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-9.
4. Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician 1997; 55:1647-54.
5. Kunin CM. Resistance to antimicrobial drugs: A worldwide calamity. Ann Intern Med 1993; 118:557-61.
6. Neu HC. The crisis in antibiotic resistance. Science 1992; 257:1064-73.
7. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001; 33(Suppl 3):S187-92.
8. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
9. Barry AL. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. Am J Med 1999; 107:28S-33S.
10. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31(Suppl 2):S24-8.
11. Centers for Disease Control and Prevention. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50:800-4.
12. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001; 184:794-8.
13. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. J Antimicrob Chemother 2001; 48:375-81.
14. Doern GV, Brueggemann AB, Blocker M, et al. Clonal relationships among high-level pencillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis 1998; 27:757-61.
15. McDougal LK, Facklam R, Reeves M, et al. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother 1992; 36:2176-84.
16. Munoz R, Musser JM, Crain M, et al. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: Characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis 1992; 15:112-8.
17. Jabes D, Nachman S, Tomasz A. Penicillin-binding protein families: Evidence for the clonal nature of penicillin resistance in clinical isolates of pneumococci. J Infect Dis 1989; 159:16-25.
18. Levy SB. Multidrug resistance - A sign of the times [editorial comment]. N Engl J Med 1998; 338:1376-8.
19. Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe. J Antimicrob Chemother 1991; 28:31-8.
20. Sahm DF, Karlowsky JA, Kelly LJ, et al. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-Year longitudinal analysis. Antimicrob Agents Chemother 2001; 45:1037-42.
21. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7:337-41.
22. Pfaller MA, Acar J, Jones RN, Verhoef J, Turnidge J, Sader HS. Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program. Clin Infect Dis 2001; 32(Suppl 2):S156-67.
23. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43:410-2.
24. Jorgensen JH, Weigel LM, Ferraro JM, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates, including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999;43:329-34.
25. Jorgensen JH, Weigel LM, Swenson JM, Whitney CG, Ferraro JM, Tenover FC. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:2962-8.
26. Kohler T, Pechere JC. Bacterial resistance to quinolones: mechanisms and clinical implications. In: Andriole VT, ed. The Quinolones. 2d Ed. San Diego: Academic Press, 1998; 117-42.
27. Deguchi T, Fukuoka A, Yasuda M, et al. Alterations in the gyrA subunit of DNA gyrase and the parC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41:699-701.
28. Craig W. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
29. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: Focus on antibacterial agents. Clin Pharmacokinet 1995; 28:143-60.
30. Forest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
31. Blasser J. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bacterial activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
32. Ciprofloxacin [Package Insert]. West Haven, CT: Bayer, 1987.
33. Levofloxacin [Package Insert]. Raritan, NJ: Ortho Pharmaceutical, 1996.
34. Sparfloxacin [Package Insert]. Collegeville, PA: Rhone-Poulenc Roer Pharmceutical, 1997.
35. Trovofloxacin [Package Insert]. New York: Pfizer Inc., 1998.
36. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43:672-7.
37. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999; 43:79-86.
38. Pfaller MA, Jones RN, Doern GV, et al. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 1998; 42:1762-70.
39. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
40. Ambrose PG, Grasela DM. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000; 38:151-7.
41. Walker RC. The fluoroquinolones. Mayo Clin Proc 1999; 74:1030-7.
42. Sindelar G, Zhao X, Liew A, et al. Mutant prevention concentration as a measure of fiuoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000; 44:3337-43.
43. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:433-8.
44. Richardson DC, Bast D, McGeer A, Low DE. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:1911-4.
45. Smaill F. Antibiotic susceptibility and resistance testing: An overview. Can J Gastroenterol 2000; 14:871-5.
46. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
47. Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 1971; 103:845-8.
48. Lee BL, Padula AM, Kimbrough RC, et al. Infectious complications with respiratory pathogens despite ciprofloxacin therapy [letter]. N Engl J Med 1991; 325:520-1.
49. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β-lactam antibiotics. Arch Intern Med 2001; 161:2538-44.
50. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-408.
51. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998; 26:811-38.
52. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
53. Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-82.